Liver resection combined with systemic therapy offers better survival for patients with hepatocellular carcinoma and macrovascular invasion.

• Overall survival rates at 1, 3, and 5 years post-resection were 65.9%, 37.7%, and 28.6%, vastly superior to 29.3%, 10.1%, and 5.4% in non-resection groups.
• Preoperative systemic therapy led to even higher survival rates: 81.2%, 50.0%, and 40.6% at the same intervals.

Prioritizing liver resection with preoperative treatment could be key for this patient group.

PAXG shows superior efficacy over mFOLFIRINOX for patients with resectable pancreatic ductal adenocarcinoma.

• Median event-free survival (EFS) for PAXG is 16.0 months compared to 10.2 months for mFOLFIRINOX.
• EFS hazard ratio is 0.63, indicating a significant benefit for PAXG (p=0.0018).

Surgeons should consider PAXG as the preferred preoperative chemotherapy regimen for this patient population.

• Adverse events were similar between both groups, suggesting PAXG’s safety profile remains acceptable.

Robotic-assisted and laparoscopic liver resection yield better outcomes for BCLC stage 0/A hepatocellular carcinoma compared to open surgery.

• Operative times were longer for robotic (225 min) and laparoscopic (225 min) than for open (170 min, p < 0.001).
• Postoperative complications were lower for robotic (12.5%) and laparoscopic (13.4%) versus open (17.1%, p < 0.001), with fewer severe complications.
• Robotic surgery showed the highest 5-year quality-adjusted life years while laparoscopic was the most cost-effective (-$24,379/QALY).

Surgeons should consider adopting robotic and laparoscopic methods to enhance patient recovery and long-term success rates.